Clinical Trial Detail

NCT ID NCT04361058
Title Nivolumab for High-Risk MDS/AML Patients After Allogeneic Stem Cell Transplant With Post-Transplant Cyclophosphamide
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors SCRI Development Innovations, LLC
Indications

myelodysplastic syndrome

acute myeloid leukemia

Therapies

Nivolumab

Age Groups: adult senior

No variant requirements are available.